Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367286 | 0.92 | HCRTR1 (0.49) | HCRTR1HCRTR2GRM5DPP4SPHK2 | |
| SCHEMBL3368917 | 0.90 | HCRTR1 (0.58) | HCRTR1HCRTR2NPC1TSHRRAB9A | |
| SCHEMBL3366901 | 0.89 | HCRTR1 (0.61) | HCRTR1HCRTR2NPC1TSHRRAB9A | |
| SCHEMBL3367538 | 0.87 | HCRTR1 (0.53) | HCRTR1HCRTR2NPC1TSHRRAB9A | |
| SCHEMBL3365273 | 0.87 | HCRTR1 (0.53) | HCRTR1HCRTR2NPC1TSHRRAB9A | |
| SCHEMBL3366076 | 0.85 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL3366195 | 0.84 | HCRTR1 (0.56) | HCRTR1HCRTR2NPC1TSHRRAB9A | |
| SCHEMBL3370194 | 0.84 | GRM5 (0.60) | HCRTR1HCRTR2GRM5DPP4USP30 | |
| SCHEMBL3367335 | 0.84 | HCRTR1 (0.61) | HCRTR1HCRTR2NPC1TSHRRAB9A | |
| SCHEMBL3366558 | 0.84 | HCRTR1 (0.60) | HCRTR1HCRTR2HDAC3CYP2C9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532141-B1 | 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | GRUENENTHAL GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | HCRTR1 461/4885HCRTR2 146/4885NPC1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.